MCID: THR024
MIFTS: 58

Thrombosis

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Thrombosis

MalaCards integrated aliases for Thrombosis:

Name: Thrombosis 12 29 55 44 15 72
Thrombosis of Blood Vessel 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0060903
MeSH 44 D013927
UMLS 72 C0040053 C2586211

Summaries for Thrombosis

Disease Ontology : 12 A vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.

MalaCards based summary : Thrombosis, also known as thrombosis of blood vessel, is related to lateral sinus thrombosis and sagittal sinus thrombosis. An important gene associated with Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs Propranolol and Alprostadil have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and testes, and related phenotypes are no effect and homeostasis/metabolism

Wikipedia : 75 Thrombosis (from Ancient Greek I,I?IOI?I2I?IfI1I, thrA3mbA?sis "clotting" ) is the formation of a blood... more...

Related Diseases for Thrombosis

Diseases related to Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2016)
# Related Disease Score Top Affiliating Genes
1 lateral sinus thrombosis 34.8 MTHFR F9
2 sagittal sinus thrombosis 34.7 SERPINC1 F5 F3 F2
3 intracranial thrombosis 34.4 VWF SERPINC1 MTHFR F5 F3 APOH
4 cerebral sinovenous thrombosis 34.3 PROS1 F5 F3 F2 APOH
5 coronary thrombosis 34.2 VWF SERPINE1 SERPINC1 PLAT GP1BA F3
6 carotid artery thrombosis 34.2 SERPINE1 SELP PLAT F3
7 portal vein thrombosis 34.0 SERPINE1 SERPINC1 SELP MTHFR JAK2 F5
8 budd-chiari syndrome 33.7 SERPINC1 MTHFR JAK2 F5 F3 F2
9 heparin-induced thrombocytopenia 33.7 SERPINC1 F3
10 post-thrombotic syndrome 33.4 SERPINE1 SERPINC1 F5 F2
11 may-thurner syndrome 33.3 F5 APOH
12 antithrombin iii deficiency 33.2 SERPINC1 MTHFR F5 F2 APOH
13 dysfibrinogenemia 33.2 THBD SERPINC1 PLAT F5 F2
14 homocysteinemia 33.2 SERPINC1 MTHFR F5 F2
15 thrombophilia due to thrombin defect 33.0 VWF THBD SERPINE1 SERPINC1 PROC PLAT
16 factor vii deficiency 33.0 F9 F3 F2
17 protein s deficiency 32.9 SERPINC1 PROS1 MTHFR F5 F3 F2
18 afibrinogenemia 32.9 VWF F5 F3 F2
19 shwartzman phenomenon 32.9 SERPINA10 F3
20 buerger disease 32.9 SERPINE1 MTHFR F2 APOH
21 hepatic veno-occlusive disease 32.9 THBD SERPINE1 SERPINC1 PLAT F3
22 polycythemia vera 32.9 THBD SELP JAK2 F5
23 chronic venous insufficiency 32.7 SERPINE1 SELP PLAT
24 factor xii deficiency 32.7 SERPINC1 F9 F5 F3 APOH
25 protein c deficiency 32.6 THBD SERPINC1 PROC MTHFR HRG F9
26 thrombocytosis 32.6 SERPINC1 SELP JAK2 F3 F2
27 catastrophic antiphospholipid syndrome 32.5 SERPINE1 PROC MTHFR F5 F3 APOH
28 plasminogen activator inhibitor-1 deficiency 32.5 SERPINE1 PLAT
29 factor v deficiency 32.3 VWF TFPI F9 F5 F3 F2
30 pulmonary embolism 32.2 VWF SERPINE1 SERPINC1 PLAT MTHFR F9
31 antiphospholipid syndrome 32.0 VWF THBD SERPINC1 SELP PLAT MTHFR
32 essential thrombocythemia 32.0 VWF THBD SERPINE1 SELP JAK2 GP1BA
33 portal hypertension 32.0 VWF JAK2 F2
34 vasculitis 31.9 VWF THBD APOH
35 varicose veins 31.9 VWF SERPINC1 MTHFR F5 F2
36 thrombophilia due to activated protein c resistance 31.8 VWF THBD SERPINE1 SERPINC1 PLAT MTHFR
37 endocarditis 31.6 SERPINC1 PLAT F2 APOH
38 homocystinuria 31.5 SERPINC1 MTHFR F5
39 thrombophilia 31.5 VWF THBD SERPINE1 SERPINC1 PROS1 PROC
40 carotid artery occlusion 31.4 THBD F5 APOH
41 thrombophlebitis 31.4 SERPINE1 SERPINC1 PLAT MTHFR F5 F2
42 intracranial embolism 31.4 SERPINC1 PLAT F2
43 lemierre's syndrome 31.4 SERPINE1 MTHFR F3
44 eclampsia 31.4 THBD SERPINC1 MTHFR F2
45 factor viii deficiency 31.3 VWF F5 F2
46 pulmonary hypertension 31.3 VWF THBD PLAT F3
47 intracranial hypertension 31.2 SERPINE1 SERPINC1 MTHFR F5 F3 F2
48 prothrombin deficiency 31.1 F3 F2
49 intermediate coronary syndrome 31.1 VWF SERPINC1 SELP PLAT F3
50 venous insufficiency 31.1 VWF SERPINE1 SELP PLAT F2

Graphical network of the top 20 diseases related to Thrombosis:



Diseases related to Thrombosis

Symptoms & Phenotypes for Thrombosis

GenomeRNAi Phenotypes related to Thrombosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 APOH CD55 F2 F3 F5 F9

MGI Mouse Phenotypes related to Thrombosis:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 APOH F2 F3 F5 F9 GP1BA
2 cardiovascular system MP:0005385 10.34 F2 F3 F5 F9 PLAT PROC
3 hematopoietic system MP:0005397 10.28 CD55 F2 F3 F9 GP1BA JAK2
4 growth/size/body region MP:0005378 10.2 F2 F3 F5 JAK2 MTHFR PLAT
5 immune system MP:0005387 10.15 F2 F3 F9 JAK2 PLAT PROC
6 embryo MP:0005380 10.13 F2 F3 F5 F9 JAK2 PROS1
7 mortality/aging MP:0010768 10.09 APOH F2 F3 F5 F9 JAK2
8 integument MP:0010771 10.06 F2 F3 F5 JAK2 MTHFR PLAT
9 liver/biliary system MP:0005370 9.96 F5 F9 JAK2 MTHFR PROC PROS1
10 nervous system MP:0003631 9.77 F2 F3 F5 MTHFR PLAT PROC
11 respiratory system MP:0005388 9.17 F2 F3 PLAT PROC SELP SERPINE1

Drugs & Therapeutics for Thrombosis

Drugs for Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 850)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propranolol Approved, Investigational Phase 4 525-66-6 4946
2
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
3
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
4
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
5
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
6
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
9
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
10
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
11
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
12
Tinzaparin Approved Phase 4 9005-49-6, 9041-08-1 25244225
13
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
14
Sodium citrate Approved, Investigational Phase 4 68-04-2
15
Nadroparin Approved, Investigational Phase 4
16
Pancrelipase Approved, Investigational Phase 4 53608-75-6
17
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
18
Liraglutide Approved Phase 4 204656-20-2 44147092
19 Orange Approved Phase 4
20
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
21
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
22
Fenofibrate Approved Phase 4 49562-28-9 3339
23
Ezetimibe Approved Phase 4 163222-33-1 150311
24 fluindione Approved, Investigational Phase 4 957-56-2
25
Pravastatin Approved Phase 4 81093-37-0 54687
26
Morphine Approved, Investigational Phase 4 57-27-2 5288826
27
Anti-inhibitor coagulant complex Approved, Investigational Phase 4
28
Ranibizumab Approved Phase 4 347396-82-1 459903
29
Zoledronic Acid Approved Phase 4 118072-93-8 68740
30
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
31
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
32
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
33
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
34
Phenindione Approved, Investigational Phase 4 83-12-5 4760
35
acetic acid Approved Phase 4 64-19-7 176
36
Gliclazide Approved Phase 4 21187-98-4 3475
37
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
38
Canagliflozin Approved Phase 4 842133-18-0
39
Betrixaban Approved, Investigational Phase 4 330942-05-7
40 Taurolidine Approved, Investigational Phase 4 19388-87-5
41
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
43
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
44
Azathioprine Approved Phase 4 446-86-6 2265
45
Ustekinumab Approved, Investigational Phase 4 815610-63-0
46
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
47
Evolocumab Approved Phase 4 1256937-27-5
48
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
49
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
50
Glimepiride Approved Phase 4 93479-97-1 3476

Interventional clinical trials:

(show top 50) (show all 2944)
# Name Status NCT ID Phase Drugs
1 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
2 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
3 Impact of a Biological Glue (Evicel®) on the Peri Operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
4 Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial Unknown status NCT01021488 Phase 4 Rosuvastatin 20mg/d for 14days;enoxaparin only
5 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
6 Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery Unknown status NCT00733434 Phase 4 Prostaglandin E1
7 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
8 Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial Unknown status NCT01063426 Phase 4 High dose Atorvastatin+enoxaparin;Enoxaparin
9 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
10 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
11 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
12 Late Incomplete Stent Apposition Evaluation II: Vascular Effects Evaluation After Polimer and No-polimer Based Coronary Artery Drug Eluting Stent Ilmplantation. An IVUS Based Study Unknown status NCT01375855 Phase 4
13 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
14 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
15 Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs Unknown status NCT00450645 Phase 4 low molecular weight heparin
16 Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Unknown status NCT01970280 Phase 4 Enoxaparin
17 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
18 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
19 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
20 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
21 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
22 Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial Unknown status NCT01670474 Phase 4 rt-PA (2mg/2mL) actilysis;rt-PA
23 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
24 Prevención de Parto Prematuro en Gemelares: Ensayo Aleatorio Con Progesterona Vaginal. Unknown status NCT01927029 Phase 4 Progesterone;Placebo
25 A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
26 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
27 Twelve Versus 24 Months of Dual Antiplatelet Therapy in Patients With Percutaneous Coronary Intervention for In-stent Restenosis Unknown status NCT02402491 Phase 4 12 months of P2Y12 receptor antagonist;24 months of P2Y12 receptor antagonist;Aspirin
28 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
29 Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI Unknown status NCT00976092 Phase 4 Prasugrel;Bivalirudin;Clopidogrel;Heparin
30 Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
31 Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers Unknown status NCT01478282 Phase 4 Rivaroxaban;Dabigatran
32 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
33 Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery Unknown status NCT01648712 Phase 4
34 The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial Unknown status NCT03113253 Phase 4 Tranexamic Acid;Placebo
35 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
36 TITANIC-XV Trial: Prospective, Multicenter and Randomized Trial (Bioactive Bare Metal Titanium Stent Versus Everolimus Drug Eluting Stent) Unknown status NCT01510509 Phase 4
37 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
38 Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V Unknown status NCT00714545 Phase 4
39 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
40 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
41 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
42 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
43 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
44 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
45 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
46 Local Delivery of thrombolytIcs Before Thrombectomy in patientS With ST-elevatiOn myocardiaL Infarction Undergoing Primary percuTaneous Coronary interventION - The DISSOLUTION Randomized Trial Unknown status NCT01568931 Phase 4 Urokinase;Saline
47 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
48 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4 Prasugrel
49 Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing Unknown status NCT01477775 Phase 4 Oral P2Y12 receptor blocker;Customized choice for the oral P2Y12 receptor blocker
50 A Randomized Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus SirOlimus ELUting Stent With Non-Biodegradable Polymer in the Treatment of PatIents With de nOvo Coronary Artery LesioNs Unknown status NCT00825773 Phase 4

Search NIH Clinical Center for Thrombosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Abciximab
Argatroban
Bivalirudin
Eptifibatide
Pentoxifylline

Cochrane evidence based reviews: thrombosis

Genetic Tests for Thrombosis

Genetic tests related to Thrombosis:

# Genetic test Affiliating Genes
1 Thrombosis 29

Anatomical Context for Thrombosis

MalaCards organs/tissues related to Thrombosis:

41
Liver, Heart, Testes, Endothelial, Brain, Kidney, Lung

Publications for Thrombosis

Articles related to Thrombosis:

(show top 50) (show all 31257)
# Title Authors PMID Year
1
Acute mesenteric and aortic thrombosis associated with antithrombin deficiency: a rare occurrence. 9 38
19932950 2010
2
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 9 38
20004006 2010
3
Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein1 in thrombosis. 9 38
20206880 2010
4
[Relationship of von Willebrand factor gene single-nucleotide polymorphism with thrombosis diseases]. 9 38
20416208 2010
5
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. 9 38
20353989 2010
6
Emerging roles of fibronectin in thrombosis. 9 38
20116835 2010
7
Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release. 9 38
20087632 2010
8
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. 9 38
19883911 2010
9
Continuous intraarterial thrombolysis for early hepatic artery thrombosis following liver transplantation: case report. 9 38
20034941 2010
10
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. 9 38
19582452 2010
11
Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients. 9 38
19497612 2010
12
Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. 9 38
19398123 2010
13
JAK2 mutation and thrombosis in the myeloproliferative neoplasms. 9 38
20425393 2010
14
ABO blood groups and genetic risk factors for thrombosis in Croatian population. 9 38
20017223 2009
15
Thrombosis markers in hip versus knee arthroplasty: a pilot study. 9 38
20065366 2009
16
Prevalence of factor V leiden mutation in patients with thrombosis in Tunisia. 9 38
20218141 2009
17
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. 9 38
19214510 2009
18
[Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis]. 9 38
19840484 2009
19
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. 9 38
19195685 2009
20
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 9 38
19660606 2009
21
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis. 9 38
19481472 2009
22
Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. 9 38
19421222 2009
23
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. 9 38
19414836 2009
24
Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis. 9 38
19192108 2009
25
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. 9 38
19193675 2009
26
The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. 9 38
19353312 2009
27
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. 9 38
19117960 2009
28
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. 9 38
19180123 2009
29
Role of pulsatile perfusion with tissue plasminogen activator in deceased donor kidneys with extensive glomerular thrombosis. 9 38
19249467 2009
30
Mitogen-activated protein kinases in hemostasis and thrombosis. 9 38
18826389 2008
31
Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass. 9 38
18575842 2008
32
Acute left atrial thrombosis during anticoagulant therapy in a patient with antithrombin deficiency. 9 38
19014009 2008
33
Role of the protein C pathway in the extraintestinal thrombosis associated with murine colitis. 9 38
18514072 2008
34
Acute effects of different alcoholic beverages on vascular endothelium, inflammatory markers and thrombosis fibrinolysis system. 9 38
18295937 2008
35
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. 9 38
18375790 2008
36
Heparin induced thrombocytopenia with thrombosis: a two step process? 9 38
18702877 2008
37
The paradoxical association between inherited factor VII deficiency and venous thrombosis. 9 38
18282149 2008
38
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. 9 38
18616871 2008
39
Arterial thrombosis associated with factor V Leiden and methylenetetrahydrofolate reductase C677T mutation in childhood membranous glomerulonephritis. 9 38
18030499 2008
40
Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. 9 38
18208809 2008
41
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis. 9 38
18590927 2008
42
Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. 9 38
18045662 2008
43
A fulminant case of renal vein thrombosis in a patient with autoimmune disorder and membranous nephropathy. 9 38
18480584 2008
44
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. 9 38
17261530 2007
45
Plasminogen activator inhibitor-1 in vascular thrombosis. 9 38
17896948 2007
46
Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. 9 38
17908667 2007
47
Late drug-eluting stent thrombosis and erythropoietin: cause and effect? 9 38
17446131 2007
48
Combined effects of thrombosis pathway gene variants predict cardiovascular events. 9 38
17677000 2007
49
Lupus anticoagulant activity as a thrombosis risk factor in lung adenocarcinoma patients. 9 38
17804532 2007
50
Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. 9 38
17534796 2007

Variations for Thrombosis

Expression for Thrombosis

Search GEO for disease gene expression data for Thrombosis.

Pathways for Thrombosis

Pathways related to Thrombosis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 THBD TFPI SERPINC1 PROS1 PROC F9
2
Show member pathways
12.63 VWF THBD TFPI SERPINE1 SERPINC1 SELP
3
Show member pathways
12.17 VWF THBD TFPI SERPINE1 SERPINC1 PROS1
4
Show member pathways
12.13 SERPINE1 PLAT MTHFR F2
5
Show member pathways
12.05 THBD SELP PROS1 PROC F2
6 11.91 VWF THBD TFPI SERPINE1 SERPINC1 PROS1
7
Show member pathways
11.79 PROS1 PROC F9 F2
8 11.73 THBD SERPINE1 JAK2 F3
9
Show member pathways
11.7 VWF GP1BA F2
10 11.33 SELP PLAT GP1BA
11 10.8 PROS1 PROC F9 F2
12 10.66 SERPINE1 PLAT HRG
13 10.64 VWF GP1BA
14 10.51 VWF GP1BA

GO Terms for Thrombosis

Cellular components related to Thrombosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.97 THBD TFPI PLAT HRG GP1BA F3
2 endoplasmic reticulum lumen GO:0005788 9.88 SERPINC1 SERPINA10 PROC F9 F5 F2
3 extracellular region GO:0005576 9.83 VWF TFPI SERPINE1 SERPINC1 SERPINA10 PROS1
4 blood microparticle GO:0072562 9.78 SERPINC1 PROS1 HRG F2
5 Golgi lumen GO:0005796 9.73 PROS1 PROC F9 F2
6 collagen-containing extracellular matrix GO:0062023 9.7 VWF SERPINE1 SERPINC1 PLAT HRG F3
7 platelet alpha granule lumen GO:0031093 9.65 VWF SERPINE1 PROS1 HRG F5
8 extracellular space GO:0005615 9.5 THBD TFPI SERPINE1 SERPINC1 SERPINA10 SELP
9 platelet alpha granule GO:0031091 9.49 VWF F5
10 plasma membrane GO:0005886 10.3 THBD TFPI SERPINE1 SERPINC1 SELP PROS1
11 extracellular exosome GO:0070062 10.1 VWF SERPINE1 SERPINC1 SERPINA10 PROS1 PLAT

Biological processes related to Thrombosis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.98 VWF SERPINE1 SELP PROS1 HRG F5
2 ER to Golgi vesicle-mediated transport GO:0006888 9.95 PROS1 PROC F9 F5 F2 CD55
3 negative regulation of endopeptidase activity GO:0010951 9.93 TFPI SERPINE1 SERPINC1 SERPINA10 PROS1 HRG
4 cellular protein metabolic process GO:0044267 9.91 SERPINC1 SERPINA10 PROC F5 F2
5 response to lipopolysaccharide GO:0032496 9.86 THBD TFPI SELP JAK2
6 negative regulation of peptidase activity GO:0010466 9.84 TFPI SERPINE1 SERPINC1 SERPINA10
7 platelet activation GO:0030168 9.83 VWF HRG GP1BA F2
8 blood coagulation, intrinsic pathway GO:0007597 9.8 VWF GP1BA F9 F2 APOH
9 regulation of complement activation GO:0030449 9.77 PROS1 F2 CD55
10 regulation of blood coagulation GO:0030193 9.77 SERPINC1 HRG GP1BA F2 APOH
11 hemostasis GO:0007599 9.77 VWF THBD TFPI SERPINC1 SERPINA10 PROS1
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 SELP JAK2 F2
13 fibrinolysis GO:0042730 9.73 SERPINE1 PROS1 PLAT HRG GP1BA F2
14 negative regulation of fibrinolysis GO:0051918 9.72 THBD SERPINE1 HRG F2 APOH
15 positive regulation of blood coagulation GO:0030194 9.67 SERPINE1 F2 APOH
16 negative regulation of blood coagulation GO:0030195 9.63 THBD TFPI SERPINE1 PROS1 PROC APOH
17 plasminogen activation GO:0031639 9.59 PLAT APOH
18 negative regulation of platelet activation GO:0010544 9.58 THBD F2
19 negative regulation of cell adhesion mediated by integrin GO:0033629 9.57 SERPINE1 HRG
20 blood coagulation, extrinsic pathway GO:0007598 9.55 TFPI F3
21 blood coagulation GO:0007596 9.5 VWF THBD TFPI SERPINC1 SERPINA10 PROS1

Molecular functions related to Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.91 THBD SELP PROS1 PROC F9 F2
2 signaling receptor binding GO:0005102 9.85 SERPINE1 PLAT JAK2 HRG F2
3 serine-type peptidase activity GO:0008236 9.71 PROC PLAT F9 F2
4 serine-type endopeptidase activity GO:0004252 9.65 PROC PLAT F9 F3 F2
5 peptidase inhibitor activity GO:0030414 9.62 TFPI SERPINE1 SERPINC1 SERPINA10
6 protease binding GO:0002020 9.46 VWF SERPINE1 SERPINC1 F3
7 immunoglobulin binding GO:0019865 9.37 VWF HRG
8 serine-type endopeptidase inhibitor activity GO:0004867 9.35 TFPI SERPINE1 SERPINC1 SERPINA10 HRG
9 heparin binding GO:0008201 9.1 SERPINC1 SERPINA10 SELP HRG F2 APOH

Sources for Thrombosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....